{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:56:43Z","timestamp":1774328203710,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,7,29]],"date-time":"2011-07-29T00:00:00Z","timestamp":1311897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s11940-011-0140-y","type":"journal-article","created":{"date-parts":[[2011,7,28]],"date-time":"2011-07-28T05:40:50Z","timestamp":1311831650000},"page":"508-519","source":"Crossref","is-referenced-by-count":38,"title":["Treatment of Apathy in Huntington\u2019s Disease and Other Movement Disorders"],"prefix":"10.1007","volume":"13","author":[{"given":"Ashok","family":"Krishnamoorthy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Craufurd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,7,29]]},"reference":[{"key":"140_CR1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"Huntington\u2019s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell. 1993;72:971\u201383.","journal-title":"Cell"},{"key":"140_CR2","doi-asserted-by":"crossref","unstructured":"Watt DC, Seller A: A clinico-genetic study of psychiatric disorder in Huntington\u2019s chorea. Psychol Med Monogr Suppl 1993:23.","DOI":"10.1017\/S0264180100001193"},{"key":"140_CR3","first-page":"179","volume-title":"Behavioral neurology of movement disorders","author":"JL Cummings","year":"1995","unstructured":"Cummings JL. Behavioral and psychiatric symptoms associated with Huntington\u2019s disease. In: Weiner WJ, Lang AE, editors. Behavioral neurology of movement disorders. New York: Raven; 1995. p. 179\u201386."},{"key":"140_CR4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp.71.3.310","volume":"71","author":"JS Paulsen","year":"2001","unstructured":"Paulsen JS, Ready RE, Hamilton JM, et al. Neuropsychiatric aspects of Huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 2001;71:310\u201314.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"140_CR5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.neuropsych.19.4.441","volume":"19","author":"E Duijn Van","year":"2007","unstructured":"Van Duijn E, Kingma EM, van der Mast RC. Psychopathology in verified Huntington\u2019s disease gene carriers. J Neuropsychiatry Clin Neurosci. 2007;19:441\u20138.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"4","key":"140_CR6","first-page":"219","volume":"14","author":"D Craufurd","year":"2001","unstructured":"Craufurd D, Thompson JC, Snowden JS. Behavioral changes in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14(4):219\u201326.","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol."},{"issue":"3","key":"140_CR7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1176\/appi.neuropsych.21.3.266","volume":"21","author":"P Naarding","year":"2009","unstructured":"Naarding P, Janzing JG, Eling P, van der Werf S, Kremer B. Apathy is not depression in Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci. 2009;21(3):266\u201370.","journal-title":"J Neuropsychiatry Clin Neurosci."},{"issue":"4","key":"140_CR8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/jnnp.2009.181149","volume":"82","author":"H Rickards","year":"2011","unstructured":"Rickards H, De Souza J, van Walsem M, van Duijn E, Simpson SA, Squitieri F, et al. The European Huntington\u2019s Disease network. Factor analysis of behavioural symptoms in Huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 2011;82(4):411\u20132.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"140_CR9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00001199-200507000-00009","volume":"20","author":"RS Marin","year":"2005","unstructured":"Marin RS, Wilkosz PA. Disorders of diminished motivation. J Head Trauma Rehabil. 2005;20:377\u201388.","journal-title":"J Head Trauma Rehabil"},{"issue":"Suppl 1","key":"140_CR10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1017\/S1041610200006918","volume":"12","author":"SE Starkstein","year":"2000","unstructured":"Starkstein SE. Apathy and withdrawal. Int Psychogeriatr. 2000;12 Suppl 1:135\u20138.","journal-title":"Int Psychogeriatr"},{"issue":"2","key":"140_CR11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/mds.10041","volume":"17","author":"V Isella","year":"2002","unstructured":"Isella V, Melzi P, Grimaldi M, Iurlaro S, Piolti R, Ferrarese C, et al. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson\u2019s disease. Mov Disord. 2002;17(2):366\u201371.","journal-title":"Mov Disord."},{"issue":"10","key":"140_CR12","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/jnnp.2007.136895","volume":"79","author":"SE Starkstein","year":"2008","unstructured":"Starkstein SE, Leentjens AF. The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry. 2008;79(10):1088\u201392.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"7","key":"140_CR13","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/cercor\/bhj043","volume":"16","author":"R Levy","year":"2006","unstructured":"Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex. 2006;16(7):916\u201328.","journal-title":"Cereb Cortex."},{"issue":"4","key":"140_CR14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1017\/S104161020200858X","volume":"14","author":"S Gauthier","year":"2002","unstructured":"Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer\u2019s disease. Int Psychogeriatr. 2002;14(4):389\u2013404.","journal-title":"Int Psychogeriatr"},{"issue":"2","key":"140_CR15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/gps.2507","volume":"26","author":"G Waldemar","year":"2011","unstructured":"Waldemar G, Gauthier S, Jones R, Wilkinson D, Cummings J, Lopez O, et al. Effect of donepezil on emergence of apathy in mild to moderate Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2011;26(2):150\u20137.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"7","key":"140_CR16","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/01.wnl.0000238106.10423.00","volume":"67","author":"E Cubo","year":"2006","unstructured":"Cubo E, Shannon KM, Tracy D, Jaglin JA, Bernard BA, Wuu J, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67(7):1268\u201371.","journal-title":"Neurology."},{"issue":"5","key":"140_CR17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1185\/03007991003688888","volume":"26","author":"S Gauthier","year":"2010","unstructured":"Gauthier S, Juby A, Dalziel W, R\u00e9hel B, Schecter R. EXPLORE investigators. Effects of rivastigmine on common symptomatology of Alzheimer\u2019s disease (EXPLORE). Curr Med Res Opin. 2010;26(5):1149\u201360.","journal-title":"Curr Med Res Opin."},{"issue":"6","key":"140_CR18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1046\/j.1468-1331.2002.00447_4.x","volume":"9","author":"U Rot","year":"2002","unstructured":"Rot U, Kobal J, Sever A, Pirtosek Z, Mesec A. Rivastigmine in the treatment of Huntington\u2019s disease. Eur J Neurol. 2002;9(6):689\u201390.","journal-title":"Eur J Neurol."},{"issue":"1","key":"140_CR19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.wnf.0000240945.44370.f0","volume":"30","author":"M Tommaso de","year":"2007","unstructured":"de Tommaso M, Difruscolo O, Sciruicchio V, Specchio N, Livrea P. Two years\u2019 follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol. 2007;30(1):43\u20136.","journal-title":"Clin Neuropharmacol."},{"issue":"11","key":"140_CR20","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/00023210-200620110-00006","volume":"20","author":"H Brodaty","year":"2006","unstructured":"Brodaty H, Woodward M, Boundy K, Barnes N, Allen G, NATURE Investigators. A naturalistic study of galantamine for Alzheimer\u2019s disease. CNS Drugs. 2006;20(11):935\u201343.","journal-title":"CNS Drugs"},{"issue":"3","key":"140_CR21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/JCP.0b013e318172b479","volume":"28","author":"N Herrmann","year":"2008","unstructured":"Herrmann N, Rothenburg LS, Black SE, Ryan M, Liu BA, Busto UE, et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol. 2008;28(3):296\u2013301.","journal-title":"J Clin Psychopharmacol."},{"issue":"4","key":"140_CR22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/JGP.0b013e3181cabcf6","volume":"18","author":"PR Padala","year":"2010","unstructured":"Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wengel SP, Potter JF, et al. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry. 2010;18(4):371\u20134.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"2","key":"140_CR23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.neuropsych.21.2.216","volume":"21","author":"DR Spiegel","year":"2009","unstructured":"Spiegel DR, Kim J, Greene K, Conner C, Zamfir D. Apathy due to cerebrovascular accidents successfully treated with methylphenidate: a case series. J Neuropsychiatry Clin Neurosci. 2009;21(2):216\u20139.","journal-title":"J Neuropsychiatry Clin Neurosci."},{"issue":"1","key":"140_CR24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/02688690500080893","volume":"19","author":"S Keenan","year":"2005","unstructured":"Keenan S, Mavaddat N, Iddon J, Pickard JD, Sahakian BJ. Effects of methylphenidate on cognition and apathy in normal pressure hydrocephalus: a case study and review. Br J Neurosurg. 2005;19(1):46\u201350.","journal-title":"Br J Neurosurg."},{"key":"140_CR25","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1046\/j.1532-5415.2001.49092.x","volume":"49","author":"IH Jansen","year":"2001","unstructured":"Jansen IH, Olde Rikkert MG, Hulsbos HA, Hoefnagels WH. Toward individualized evidence-based medicine: five \u2018N of 1\u2019 trials of methylphenidate in geriatric patients. J Am Geriatr Soc. 2001;49:474\u20136.","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"140_CR26","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1177\/0883073808314152","volume":"23","author":"JL Waugh","year":"2008","unstructured":"Waugh JL, Miller VS, Chudnow RS, Dowling MM. Juvenile Huntington disease exacerbated by methylphenidate: case report. J Child Neurol. 2008;23(7):807\u20139.","journal-title":"J Child Neurol."},{"issue":"2","key":"140_CR27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/mds.22307","volume":"24","author":"L Marsh","year":"2009","unstructured":"Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson\u2019s disease: a pilot open-label study. Mov Disord. 2009;24(2):277\u201382.","journal-title":"Mov Disord."},{"key":"140_CR28","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.0b013e3181ebdd79","volume":"75","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75:448\u201355.","journal-title":"Neurology"},{"issue":"5","key":"140_CR29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/JCP.0b013e3181b2ac0a","volume":"29","author":"LJ Beglinger","year":"2009","unstructured":"Beglinger LJ, Adams WH, Paulson H, Fiedorowicz JG, Langbehn DR, Duff K, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol. 2009;29(5):484\u20137.","journal-title":"J Clin Psychopharmacol."},{"issue":"2","key":"140_CR30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1345\/aph.1H302","volume":"41","author":"PR Padala","year":"2007","unstructured":"Padala PR, Burke WJ, Bhatia SC. Modafinil therapy for apathy in an elderly patient. Ann Pharmacother. 2007;41(2):346\u20139.","journal-title":"Ann Pharmacother."},{"issue":"13","key":"140_CR31","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0028-3932(02)00108-2","volume":"40","author":"V Czernecki","year":"2002","unstructured":"Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B. Motivation, reward, and Parkinson\u2019s disease: influence of dopatherapy. Neuropsychologia. 2002;40(13):2257\u201367.","journal-title":"Neuropsychologia."},{"issue":"2","key":"140_CR32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/02699050410001719989","volume":"19","author":"G Newburn","year":"2005","unstructured":"Newburn G, Newburn D. Selegiline in the management of apathy following traumatic brain injury. Brain Inj. 2005;19(2):149\u201354.","journal-title":"Brain Inj."},{"issue":"6","key":"140_CR33","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.neuchi.2008.10.009","volume":"55","author":"F Moutaouakil","year":"2009","unstructured":"Moutaouakil F, El Otmani H, Fadel H, Slassi I. Severe apathy following head injury: improvement with selegiline treatment. Neurochirurgie. 2009;55(6):551\u20134.","journal-title":"Neurochirurgie"},{"issue":"1","key":"140_CR34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/02699059509004571","volume":"9","author":"R Reekum Van","year":"1995","unstructured":"Van Reekum R, Bayley M, Garner S, Burke IM, Fawcett S, Hart A, et al. N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj. 1995;9(1):49\u201353.","journal-title":"Brain Inj."},{"issue":"7","key":"140_CR35","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/02699050400025059","volume":"19","author":"MF Kraus","year":"2005","unstructured":"Kraus MF, Smith GS, Butters M, Donnell AJ, Dixon E, Yilong C, et al. Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET). Brain Inj. 2005;19(7):471\u20139.","journal-title":"Brain Inj."},{"key":"140_CR36","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneur.60.7.996","volume":"60","author":"P O\u2019Suilleabhain","year":"2003","unstructured":"O\u2019Suilleabhain P, Dewey Jr RB. A randomized trial of amantadine in Huntington disease. Arch Neurol. 2003;60:996\u20138.","journal-title":"Arch Neurol."},{"issue":"5","key":"140_CR37","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1212\/WNL.59.5.694","volume":"59","author":"L Verhagen Metman","year":"2002","unstructured":"Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, et al. Huntington\u2019s disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002;59(5):694\u20139.","journal-title":"Neurology"},{"issue":"12","key":"140_CR38","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1007\/s00415-002-0903-1","volume":"249","author":"S Debette","year":"2002","unstructured":"Debette S, Kozlowski O, Steinling M, Rousseaux M. Levodopa and bromocriptine in hypoxic brain injury. J Neurol. 2002;249(12):1678\u201382.","journal-title":"J Neurol."},{"issue":"1","key":"140_CR39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-0404.1977.tb01407.x","volume":"56","author":"L Frattola","year":"1977","unstructured":"Frattola L, Albiazzati MG, Spano PF, Trabucchi M. Treatment of Huntington\u2019s chorea with bromocriptine. Acta Neurol Scand. 1977;56(1):37\u201345.","journal-title":"Acta Neurol Scand."},{"issue":"1","key":"140_CR40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/0269881104043284","volume":"18","author":"C Corcoran","year":"2004","unstructured":"Corcoran C, Wong ML, O\u2019Keane V. Bupropion in the management of apathy. J Psychopharmacol. 2004;18(1):133\u20135.","journal-title":"J Psychopharmacol."},{"key":"140_CR41","first-page":"A29","volume":"79","author":"K Strassburger","year":"2008","unstructured":"Strassburger K, Andrich J, Saft C. Bupropion: first experience in Huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 2008;79:A29\u201330.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"140_CR42","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.clinthera.2010.10.012","volume":"32","author":"A Siniscalchi","year":"2010","unstructured":"Siniscalchi A, Gallelli L, Tolotta GA, Loiacono D, De Sarro G. Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis. Clin Ther. 2010;32(12):2030\u20134.","journal-title":"Clin Ther."},{"issue":"8","key":"140_CR43","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/(SICI)1099-1166(199908)14:8<633::AID-GPS996>3.0.CO;2-W","volume":"14","author":"M Hopman-Rock","year":"1999","unstructured":"Hopman-Rock M, Staats PG, Tak EC, Dr\u00f6es RM. The effects of a psychomotor activation programme for use in groups of cognitively impaired people in homes for the elderly. Int J Geriatr Psychiatry. 1999;14(8):633\u201342.","journal-title":"Int J Geriatr Psychiatry."},{"key":"140_CR44","doi-asserted-by":"crossref","unstructured":"Ferrero-Arias J, Go\u00f1i-Im\u00edzcoz M, Gonz\u00e1lez-Bernal J, Lara-Ortega F, da Silva-Gonz\u00e1lez A, D\u00edez-Lopez M. The efficacy of nonpharmacological treatment for dementia-related apathy. Alzheimer Dis Assoc Disord. 2011 Feb 22 (Epub ahead of print).","DOI":"10.1097\/WAD.0b013e3182087dbc"},{"issue":"4","key":"140_CR45","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2190\/PM.37.4.a","volume":"37","author":"JA Staal","year":"2007","unstructured":"Staal JA, Sacks A, Matheis R, Collier L, Calia T, Hanif H, et al. The effects of Snoezelen (multi-sensory behavior therapy) and psychiatric care on agitation, apathy, and activities of daily living in dementia patients on a short term geriatric psychiatric inpatient unit. Int J Psychiatry Med. 2007;37(4):357\u201370.","journal-title":"Int J Psychiatry Med."},{"issue":"2","key":"140_CR46","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/WAD.0b013e3181630b6f","volume":"22","author":"A Raglio","year":"2008","unstructured":"Raglio A, Bellelli G, Traficante D, Gianotti M, Ubezio MC, Villani D, et al. Efficacy of music therapy in the treatment of behavioral and psychiatric symptoms of dementia. Alzheimer Dis Assoc Disord. 2008;22(2):158\u201362.","journal-title":"Alzheimer Dis Assoc Disord."},{"issue":"12","key":"140_CR47","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1177\/0269215510376004","volume":"24","author":"YX Niu","year":"2010","unstructured":"Niu YX, Tan JP, Guan JQ, Zhang ZQ, Wang LN. Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer\u2019s disease: a randomized controlled trial. Clin Rehabil. 2010;24(12):1102\u201311.","journal-title":"Clin Rehabil."}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-011-0140-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-011-0140-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-011-0140-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T13:53:11Z","timestamp":1560433991000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-011-0140-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,29]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["140"],"URL":"https:\/\/doi.org\/10.1007\/s11940-011-0140-y","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,29]]}}}